Indivior seeks Health Canada approval for Sublocade injection to treat moderate to severe opioid use disorder

Indivior PLC, a global specialty pharmaceutical company, announced that it has filed a New Drug Submission (NDS) with Health Canada's Therapeutic Drugs Directorate for Sublocade (buprenorphine

More From BioPortfolio on "Indivior seeks Health Canada approval for Sublocade injection to treat moderate to severe opioid use disorder"